Summary
The product Halotest, manufactured by Driada Medical, underwent testing to assess its content and potency. The sample, identified by batch number 062435, was analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis confirmed the presence of Fluoxymesterone, with a measured amount of 5.98 mg per pill, slightly exceeding the label specification of 5 mg per pill. This represents a 19.6% variance, indicating the product contains more active ingredient than specified.
The testing process was initiated on 21 February 2022, with the sample received on 22 February 2022, and the analysis completed on 28 February 2022. The sample was submitted and funded by Driada Medical, which warrants careful scrutiny of the results. Notably, the sample was retested twice for verification, ensuring consistent findings. This report is intended for harm reduction and educational purposes, providing transparency about the product’s composition.
Detailed Report
Product Overview
- Manufacturer: Driada Medical
- Product Name: Halotest
- Active Ingredient: Fluoxymesterone
- Batch Number: 062435
- Expiration Date: Not provided
- Delivery Method: Oral tablet
Sample Acquisition and Testing
- Task Number: #18694
- Testing Ordered: 21 February 2022
- Sample Received: 22 February 2022
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Driada Medical
- Analysis Paid For By: Driada Medical
Testing Results
- Specification: 5 mg Fluoxymesterone per pill
- Measured Amount: 5.98 mg per pill
- Accuracy: 119.6% of the label claim
- Variance: +19.6% above the label claim
Verification Details
- Verification URL:
https://janoshik.com/tests/18694_GDZ84EMZNQ9D - Originally Published: https://thinksteroids.com/community/posts/2920247/
Evaluation of Manufacturer-Funded Testing
Since this test was both submitted and funded by Driada Medical, the findings require careful evaluation. Manufacturer-funded testing raises concerns about potential bias, such as the selection of optimal batches for analysis. However, Janoshik Analytical is recognized for its transparency and reliability, which lends credibility to the results. Additionally, the retesting of this sample enhances confidence in the findings.
Independent third-party testing would further validate these results and provide greater assurance to consumers.
Conclusion
The analysis of Halotest confirmed that each pill contains 5.98 mg of Fluoxymesterone, exceeding the specified dosage of 5 mg per pill by 19.6%. While this variance indicates accurate and consistent dosing above the label claim, it highlights the importance of lab testing to verify the quality and reliability of anabolic steroid products. This report serves as a critical tool for harm reduction and informed decision-making.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-funded testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
